Fresenius Medical Care (FME.DE) Stock Price
Fresenius Medical Care Price
Revenue has compounded at 6.0% per year over the past 19 years to 19.63 B EUR. Earnings per share have grown at 4.9% per year over the last 19 years. Fresenius Medical Care's net margin stands at 5.0%, broadly stable from 5.5% several years earlier. Fresenius Medical Care currently offers a dividend yield of about 3.65%. The payout ratio is around 42% of earnings. The dividend has grown at 6.8% per year over the past 19 years. Analysts set a median price target of 46.92 EUR, implying 18.9% above the current price. Of 27 analysts, 11 rate the stock a buy — an overall Hold consensus.
Fresenius Medical Care stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Fresenius Medical Care business model & stock analysis
Frequently asked questions about Fresenius Medical Care
Fresenius Medical Care AG is a leading global provider of dialysis products, services, and solutions for patients with chronic kidney failure. The company's business model revolves around providing high-quality dialysis care to patients in over 120 countries. Fresenius Medical Care AG offers a comprehensive range of dialysis machines, dialyzers, and other related products to ensure efficient and effective treatment. Furthermore, the company operates a network of dialysis clinics, providing personalized care for patients worldwide. With a focus on innovation, research, and development, Fresenius Medical Care AG continuously strives to enhance patient outcomes and improve the overall quality of life for individuals with kidney disease.
Fresenius Medical Care AG is primarily active in the healthcare industry.
The main competitors of Fresenius Medical Care AG in the market are DaVita Inc., Baxter International Inc., and B. Braun Melsungen AG.
Fresenius Medical Care AG is a leading global healthcare company specializing in dialysis products and services. Established in 1996, it stemmed from the merger of Fresenius AG and National Medical Care. With its headquarters in Germany, the company has expanded its reach worldwide, operating in nearly 150 countries. Fresenius Medical Care AG is renowned for its expertise in renal therapy, offering innovative dialysis machines, dialyzers, and related medical supplies. As a market leader, it provides life-saving treatments to millions of people suffering from chronic kidney disease. The company's commitment to delivering high-quality care and advancing renal healthcare has made Fresenius Medical Care AG a trusted name in the medical industry.
Fresenius Medical Care AG, a leading healthcare company, has achieved significant milestones throughout its history. It pioneered the development of advanced dialysis products and services, revolutionizing the treatment of end-stage renal disease. The company has established a global presence, operating in over 120 countries and serving millions of patients worldwide. Additionally, Fresenius Medical Care AG has continuously expanded its business through strategic acquisitions and collaborations, strengthening its position as a market leader in dialysis care. With a commitment to research and development, the company has achieved breakthrough innovations in dialysis technology, enhancing patient outcomes and quality of life. Overall, Fresenius Medical Care AG’s impressive achievements have solidified its reputation as a trusted provider of renal therapies.
Fresenius Medical Care AG is primarily present in various countries and regions across the globe. With a strong global presence, the company operates in more than 150 countries and regions, including the United States, Germany, Asia-Pacific, Latin America, and Europe. Its widespread international network enables Fresenius Medical Care AG to provide advanced renal care products, services, and solutions to patients worldwide. As the global leader in dialysis and kidney care, Fresenius Medical Care AG continues to expand its reach and impact, ensuring quality healthcare for patients globally.
Fresenius Medical Care AG represents values of quality, innovation, and patient-centered care. With a dedicated corporate philosophy, the company focuses on providing life-saving dialysis products, therapies, and services to patients worldwide. The commitment to excellence, compassion, and continuous advancement in medical technology enables Fresenius Medical Care AG to enhance patients' quality of life and deliver optimal renal care. As a global leader in the field, Fresenius Medical Care AG maintains a strong emphasis on scientific research, sustainability, and delivering efficient healthcare solutions for patients suffering from chronic kidney diseases.
Analysts currently set an average price target of 45.79 EUR for the Fresenius Medical Care stock (median: 46.92 EUR), implying +20.6 % versus the latest price. The consensus is based on 27 analyst ratings.
27 analysts currently rate the Fresenius Medical Care stock: 11 recommend buying, 9 holding and 7 selling. For 2026, analysts expect Fresenius Medical Care to generate revenue of 19.45 B EUR and earnings per share of 4.19 EUR.
The Fresenius Medical Care share (FME.DE) is listed on 10 stock exchanges, including: London (0H9X.L), SIX (Zürich) (FMEEUR.SW), XETRA (FME.DE), Frankfurt (FME.F), München (FME.MU), Düsseldorf (FME.DU), Hamburg (FME.HM), Wien (FME.VI).
Fresenius Medical Care AG is a leading provider of products and services for the dialysis treatment of patients with kidney failure. The company is headquartered in Bad Homburg, Germany, and operates in over 120 countries worldwide. Fresenius Medical Care also operates its own dialysis centers and offers various other medical services. The business model of Fresenius Medical Care includes three business segments: dialysis products, services related to dialysis treatment, and the care of patients with chronic diseases. In the field of dialysis products, Fresenius Medical Care develops and produces a wide range of dialysis equipment and reagents. These products are sold to both their own dialysis centers and other medical facilities worldwide. Thanks to technological innovations in dialysis treatment, medical professionals can offer patients better outcomes and a higher quality of life. In the second business segment, Fresenius Medical Care provides services related to dialysis treatment. The company operates and manages its own dialysis centers and also provides the necessary medical professionals. Additionally, Fresenius Medical Care offers technical support and training for the use of their own dialysis products. These services are an important part of the business model as they ensure both the sales of their own products and the high-quality medical care of patients. A third business segment of Fresenius Medical Care is the care of patients with chronic diseases. Through the use of data analysis and telemedicine technologies, medical professionals from Fresenius Medical Care can actively care for patients - both online and through home visits. The goal is to improve the health of patients and avoid hospital stays. The business model of Fresenius Medical Care is based on preventive health care and support for people with chronic diseases such as kidney failure. By providing high-quality products and services and establishing a comprehensive patient care program, Fresenius Medical Care strengthens its position as a leading provider in dialysis treatment. In recent years, Fresenius Medical Care has also increased its investment in research and development of innovative treatment methods to continuously improve the quality of medical care for patients with chronic diseases. The extensive expertise in this field enables the development of new treatment modalities, including digital solutions, that benefit patients. Overall, Fresenius Medical Care is an innovative company specializing in the provision of products and services for dialysis treatment. By combining technological innovations, a comprehensive patient care program, and a constant focus on the needs of medical professionals in the global healthcare industry, the company relies on a forward-looking, promising business model in a sector of growing importance.
The expected revenue of Fresenius Medical Care is 19.45 B EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Fresenius Medical Care is 1.20 B EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Fresenius Medical Care is currently 9.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fresenius Medical Care stock.
The price-to-sales ratio (P/S) of Fresenius Medical Care is currently 0.58. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fresenius Medical Care stock.
The Eulerpool Quality Score for Fresenius Medical Care is 3/10.
The ISIN of Fresenius Medical Care is DE0005785802. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Fresenius Medical Care is 578580. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Fresenius Medical Care is FME.DE. The ticker symbol is used to trade Fresenius Medical Care shares on the stock exchange.
Fresenius Medical Care stock
Fresenius Medical Care Peer Group
Fresenius Medical Care Ticker
Fresenius Medical Care FIGI
All fundamentals and in-depth analysis of Fresenius Medical Care
Our stock analysis for Fresenius Medical Care stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fresenius Medical Care. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.